Rocket Pharmaceuticals/$RCKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Primary listing
Employees
202
Headquarters
Website
RCKT Metrics
BasicAdvanced
$295m
-
-$1.88
0.47
-
Price and volume
Market cap
$295m
Beta
0.47
52-week high
$5.45
52-week low
$2.40
Average daily volume
2.3m
Financial strength
Current ratio
6.124
Quick ratio
5.901
Long term debt to equity
9.175
Total debt to equity
10.403
Interest coverage (TTM)
-112.39%
Profitability
EBITDA (TTM)
-202.457
Management effectiveness
Return on assets (TTM)
-35.14%
Return on equity (TTM)
-64.41%
Valuation
Price to book
1.24
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-1.676
Free cash flow yield (TTM)
-59.65%
Free cash flow per share (TTM)
-1.611
Growth
Earnings per share change (TTM)
-28.08%
3-year earnings per share growth (CAGR)
-17.17%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
RCKT News
AllArticlesVideos
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
Proactive Investors·2 months ago
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
Reuters·2 months ago
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs